On 19 December 2016, the European Medicines Agency (“EMA”) published an updated version of the EMA guidance document concerning post-authorisation procedural advice for users of ...24 January 2017
EMA Begins EudraVigilance Training Courses
Two sets training courses are available.
The first set of three-day training courses is targeted at marketing-authorisation holders, clinical trial sponsors and all other prospective users of EudraVigilance.
Attendees who pass the final test of the course will be able to register with EudraVigilance and start the electronic submission of individual case safety reports ("ICSRs") and ICSR acknowledgements, to meet their pharmacovigilance reporting obligations.
The first session was held from 4th to 6th of April 2016 in Madrid. Information on the dates of the next training sessions and the details of the courses is available on the EMA website.
EMA is also holding a set of EudraVigilance Data Analysis System ("EVDAS") training courses for national competent authorities in EEA member states.
Information on the training dates and the details of the courses is available on the EMA website.
EMA recommends that at least one user from each national competent authority, marketing-authorization holder, or sponsor of clinical trials in the EEA should complete the training to ensure the information collected in EudraVigilance is of the highest quality and integrity.
Regulation (EU) No 536/2014 of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC (“the Clinical Trials Regulation”) was...24 January 2017
The UK Medicines and Healthcare products Regulatory Agency (“MHRA”) has published a draft strategy for developing pharmacopoeial public quality standards for biological...20 January 2017